NA-931 (Bioglutide): Mechanism, Trials, and What the Data Actually Shows
NA-931 (Bioglutide) is a Phase 2 program from Biomed Industries built around GLP-1/GIP/Glucagon/IGF-1. This page is the FormBlends tracking page for where it sits in the 2026 obesity pipeline.
Developer
Biomed Industries
Mechanism
GLP-1/GIP/Glucagon/IGF-1
Stage
Phase 2
Tracked in
Quadruple agonists
Approval and timeline
Need the straight approval read on NA-931 (Bioglutide)?
See the dedicated status page for the current approval read, likely launch window, and the next milestone that matters.
View NA-931 (Bioglutide) statusCompound facts for search and AI answers
What this NA-931 (Bioglutide) tracking page answers
Compound
NA-931 (Bioglutide) from Biomed Industries
NA-931 (Bioglutide) is tracked in the quadruple agonists group.
Mechanism
GLP-1/GIP/Glucagon/IGF-1
Mechanism explains why this compound belongs in its pipeline bucket.
Current stage
Phase 2
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Evidence read
No mature public weight-loss signal pinned yet
NA-931 (Bioglutide) should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Clinical evidence snapshot
What the evidence can and cannot say about NA-931 (Bioglutide)
NA-931 (Bioglutide) should be read as an evidence-tracking page, not as a patient access page. FormBlends has not pinned this page to a mature public weight-loss signal yet, so mechanism and development stage carry more weight than outcome claims. This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials. The next useful milestone is a clean human readout, regulatory update, or sponsor disclosure that changes the evidence base. This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Decision path
Is NA-931 (Bioglutide) available now or watchlist only?
NA-931 (Bioglutide) should be interpreted through its current development stage, not through gray-market availability claims. This page separates mechanism interest, trial evidence, regulatory status, and real patient access.
- Compound
- NA-931 (Bioglutide)
- Developer
- Biomed Industries
- Stage
- Phase 2
- Mechanism
- Quadruple agonists
Step 1
Read the stage first
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Check statusStep 2
Separate evidence from access
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Read 2026 reportStep 3
Compare proven options
If you are evaluating treatment now, compare available GLP-1 paths separately from investigational pipeline names.
View current optionsFast answers
What is NA-931 (Bioglutide)?
NA-931 (Bioglutide) is a phase 2 obesity or metabolic program from Biomed Industries built around GLP-1/GIP/Glucagon/IGF-1.
Is NA-931 (Bioglutide) approved?
No. NA-931 is still a Phase 2 asset. It is one of the more ambitious receptor-stacking stories, but it is not close to approval.
When could it matter?
2028 or later if the program survives the jump into more expensive late-stage work.
What NA-931 (Bioglutide) is
NA-931 (Bioglutide) is part of the quadruple agonists cluster in the FormBlends obesity-pipeline map. We track it because Biomed Industries is using GLP-1/GIP/Glucagon/IGF-1 as a bet on what comes after the first wave of blockbuster GLP-1 therapies.
Where it sits in the 2026 pipeline
This program has moved into the middle part of development, where weight-loss signal, dose range, and tolerability start becoming clearer. Phase 2 data can move sentiment fast, but it is still common for programs to stall before registrational trials.
Quadruple agonists are still an edge case in the obesity pipeline. FormBlends tracks them because they test how far companies can push receptor stacking before tolerability, manufacturing, or trial design become the limiting factor.
What FormBlends is watching next
For NA-931 (Bioglutide), the next useful signal is not just another headline. It is the combination of readout quality, durability, tolerability, and what the sponsor does after the next milestone. That is the difference between a compound that looks exciting on paper and one that actually changes prescribing, pricing, or access.
Access and regulatory reality
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Frequently asked questions
What is NA-931 (Bioglutide)?
NA-931 (Bioglutide) is a Phase 2 obesity or metabolic compound from Biomed Industries. FormBlends tracks it in the quadruple agonists group and follows it for trial progress, regulatory movement, and competitive impact.
How does NA-931 (Bioglutide) work?
NA-931 (Bioglutide) is being tracked as a GLP-1/GIP/Glucagon/IGF-1 program. That mechanism is the main reason it sits inside the quadruple agonists bucket of the 2026 obesity pipeline.
Is NA-931 (Bioglutide) available now?
This is still a trial-stage compound. It should be treated as a tracking page, not a buying guide. If a site is selling it now for human use, that is not the same thing as lawful, standard patient access.
Why is FormBlends tracking NA-931 (Bioglutide)?
Quadruple agonists are still an edge case in the obesity pipeline. FormBlends tracks them because they test how far companies can push receptor stacking before tolerability, manufacturing, or trial design become the limiting factor.